A Study of ADX-102 in Subjects With Allergic Conjunctivitis

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2016
A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Phase 2b Evaluation of the Onset and Duration of ADX-102 Ophthalmic Drops (0.5% and 0.1%) Compared to Vehicle of ADX-102 Ophthalmic Drops in the Conjunctival Allergen Challenge (Ora-CAC®) Model of Acute Allergic Conjunctivitis.
Epistemonikos ID: 20fb4d96d834bb473ca848ec4492aaf5f068a559
First added on: May 20, 2024